6 research outputs found
Persistence of cardiovascular risk factors in patients with coronary artery diseases after percutaneous coronary interventions
Introduction: Coronary artery disease (CAD) is as a leading cause of
death and disability all around the world. Multiple risk factors have a role in the
development and progression of coronary heart disease (CHD). It is necessary to control risk
factors, to achieve optimal results of treatment. The aim of present study was to evaluate the
persistence of cardiovascular risk factors in patients with CADs after percutaneous cardiac
interventions. Methods: In an analytical-descriptive study, 150 patient with CAD and
percutaneous coronary intervention (PCI) were performed for them, and referred to Cardiology
Clinic of Shahid Madani Hospital of Tabriz University of Medical Sciences, Tabriz, Iran, from
September 2013 to September 2015, were studied. The persistence of coronary risk factors,
12-24 months after performing PCI, was evaluated. Results: The mean age of patients at time of
PCI performing was 57.90 ± 12.26 years. 72.7% of patients were male and 27.3% were female and
male to female ratio was 1 to 0.37. Dyslipidemia in 52.0% of patients, hypertension in 51.3%
patients, and diabetes mellitus (DM) in 41.3% patients were the most common underlying
comorbidities. In both before and after doing PCI, 26.7% were a smoker, and smoking rates
after doing PCI also showed no significant change (P = 0.055), and also there were no
significant changes in the physical activity of patients compared before and after performing
PCI. Conclusion: Based on the findings of the present study, dyslipidemia, hypertension, and
DM, was the most frequent underlying diseases in patients with CAD respectively. Risk factors
such as smoking, and lack of exercise, had no significant changes after performing
PCI
Effect of alpha-lipoic acid on asymmetric dimethylarginine and disability in multiple sclerosis patients: A randomized clinical trial
Background: Multiple Sclerosis (MS) is an inflammatory and demyelinating disease of the central nervous
system. Oxidative stress plays a major role in the onset and progression of MS. Asymmetric dimethylarginine
(ADMA) formation is dependent on oxidative stress status.
Objective: We examined whether alpha-lipoic acid (ALA) as a potent antioxidant could improve the Expanded
Disability Status Scale (EDSS) and decrease plasma level of ADMA in multiple sclerosis patients.
Methods: In a randomized, double-blinded clinical trial conducted at Sina Hospital in Tehran, Iran, from
September 2009 to July 2011, 24 patients with relapsing-remitting MS were divided into a treatment group
receiving ALA (1200mg/day) for 12 weeks and a control group receiving placebo. Then patients’ EDSS and
Plasma levels of ADMA were measured at baseline and 12 weeks later. Statistical analysis was done by SPSS
software version 16 using the K-S test, Chi square, Mann–Whitney U-test and Wilcoxon test.
Results: The plasma levels of ADMA in the intervention group were decreased significantly (p=0.04). Also, no
patient had increased EDSS score in the supplement group, where 2 out of 12 patients in the placebo group
experienced so. Comparing the serum level of ADMA between the two groups failed to show any significant
change in the supplement group compared with the control group.
Conclusion: Considering that ADMA is produced by oxidative stress in MS patients and leads to increase of
inflammation, ALA may have the potential of beneficial effects in them, in part, by decreasing the plasma level
of ADMA and stopping progression.
Trial registration: The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the
Irct ID: No. IRCT138812222602N2.
Funding: The authors received no financial support for the research, authorship, and/or publication of this articl